Daily Cardiology Research Analysis
Three impactful cardiology studies stood out: a multinational update to the GRACE 3.0 model providing validated in-hospital and 1-year mortality prediction and individualized benefit from early invasive management in NSTE-ACS; a nationwide cohort showing limited long-term survival benefit of oral anticoagulation after CABG-related POAF, suggesting time-limited strategies; and a Swedish register study demonstrating earlier, more complex, and more lethal cardiovascular disease in survivors of chil
Summary
Three impactful cardiology studies stood out: a multinational update to the GRACE 3.0 model providing validated in-hospital and 1-year mortality prediction and individualized benefit from early invasive management in NSTE-ACS; a nationwide cohort showing limited long-term survival benefit of oral anticoagulation after CABG-related POAF, suggesting time-limited strategies; and a Swedish register study demonstrating earlier, more complex, and more lethal cardiovascular disease in survivors of childhood, adolescent, and young adult cancers.
Research Themes
- Precision risk stratification and individualized treatment in acute coronary syndromes
- Anticoagulation strategies after postoperative atrial fibrillation following CABG
- Long-term cardiovascular burden in childhood and young adult cancer survivors
Selected Articles
1. Extension of the GRACE score for non-ST-elevation acute coronary syndrome: a development and validation study in ten countries.
Using 609,063 NSTE-ACS cases across ten countries, the updated GRACE 3.0 achieved excellent external performance for in-hospital (AUC 0.90) and 1-year mortality (time-dependent AUC 0.84). A separate individualized treatment effect model identified subgroups with substantial benefit from early invasive management (HR 0.60), while those with low predicted benefit did not.
Impact: This work modernizes a cornerstone risk tool for NSTE-ACS with robust multinational validation and enables individualized benefit estimation for early invasive strategies, potentially shaping guideline implementation and trial design.
Clinical Implications: Supports precise risk stratification and selection for early invasive management in NSTE-ACS; can enhance shared decision-making and resource allocation by targeting those most likely to benefit.
Key Findings
- External validation showed AUC 0.90 for in-hospital mortality and time-dependent AUC 0.84 for 1-year mortality across seven countries.
- Both models improved discrimination and risk reclassification compared with GRACE 2.0 and were well calibrated with favorable decision curves.
- An individualized treatment effect model identified patients with high predicted benefit from early invasive management (HR 0.60), while those with low-to-moderate benefit did not improve (HR 1.06).
Methodological Strengths
- Very large, multicountry cohort with external validation and strong discrimination/calibration.
- Use of machine learning and decision-curve analysis; independent validation of individualized treatment effects using randomized trial data (VERDICT).
Limitations
- Observational registries may introduce residual confounding and coding heterogeneity across countries.
- Generalizability to health systems or populations beyond the included countries and to evolving care patterns requires further study and implementation research.
Future Directions: Prospective implementation trials to test clinical impact, integration into electronic health records for automated risk/treatment-effect reporting, and evaluation in underrepresented regions.
BACKGROUND: The Global Registry of Acute Coronary Events (GRACE) scoring system guides the management of patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) according to current guidelines. However, broad validation of the sex-specific GRACE 3.0 in-hospital mortality model, and corresponding models for predicting long-term mortality and the personalised effect of early invasive management, are still needed. METHODS: We used data of 609 063 patients with NSTE-ACS from ten countries between Jan 1, 2005, and June 24, 2024. A machine learning model for 1-year mortality was developed in 400 054 patients from England, Wales, and Northern Ireland. Both the in-hospital mortality model and the new 1-year mortality model were externally validated in patients from Sweden, Switzerland, Germany, Denmark, Spain, the Netherlands, and Czechia. A separate machine learning model to predict the individualised effect of early versus delayed invasive coronary angiography and revascularisation on a composite primary outcome of all-cause death, non-fatal recurrent myocardial infarction, hospital admission for refractory myocardial ischaemia, or hospital admission for heart failure at a median follow-up of 4·3 years was developed and externally validated in participants from geographically different sets of hospitals in the Danish VERDICT trial. FINDINGS: The in-hospital mortality model (area under the receiver operating characteristic curve [AUC] 0·90, 95% CI 0·89-0·91) and the 1-year mortality model (time-dependent AUC 0·84, 95% CI 0·82-0·86) showed excellent discriminative abilities on external validation across all countries. Both models were well calibrated and decision curve analyses suggested favourable clinical utility. Compared with score version 2.0, both models provided improved discrimination and risk reclassification. The individualised treatment effect model effectively identified patients who would benefit from early invasive management on external validation. Patients with high predicted benefit had reduced risk of the composite outcome when randomly assigned to early invasive management (hazard ratio 0·60, 95% CI 0·41-0·88), whereas patients with no-to-moderate predicted benefit did not (1·06, 0·80-1·40; p
2. Timing and combinations of cardiovascular diseases in survivors of childhood, adolescent, and young adulthood cancer.
In a 63-year national register cohort (n=58,981 with CVD), cancer survivors diagnosed before age 25 developed CVD earlier (median 41.8 vs 49.6 years), had more multimorbidity, and experienced higher all-cause (HR 2.43) and cardiovascular (HR 2.17) mortality than matched controls. Male sex and geography increased risk, whereas higher education and marriage were protective.
Impact: Defines the timing, clustering, and elevated mortality of CVD in young cancer survivors at national scale, informing survivorship care pathways and targeted prevention.
Clinical Implications: Supports earlier, tailored cardiovascular screening and risk reduction strategies in CAYA survivors, with attention to high-risk subgroups and social determinants.
Key Findings
- Median age at first CVD was earlier in CAYA survivors than controls (41.8 vs 49.6 years; p<0.0001).
- Multimorbidity was common: 20.2% had two and 8.2% had three CVDs; combinations often involved hypertension with cerebrovascular, ischemic, or arrhythmic disease.
- All-cause mortality HR 2.43 and cardiovascular mortality HR 2.17 were higher than controls; higher education and marriage were protective factors.
Methodological Strengths
- Nationwide, register-based cohort spanning 63 years with large sample and matched controls.
- Long median follow-up (34.6 years) enabling assessment of timing, multimorbidity, and mortality.
Limitations
- Registry data lack granular treatment exposures, lifestyle factors, and detailed cardiotoxic therapy dosimetry.
- Residual confounding and generalizability beyond Sweden may limit extrapolation.
Future Directions: Linkage to oncology treatment data to identify therapy-specific CVD risks, and testing targeted cardio-oncology prevention programs in high-risk CAYA survivors.
BACKGROUND: Children, adolescents, and young adults with cancer (referred to as CAYAs) are at risk of long-term health complications, with cardiovascular disease (CVD) being a major concern. In addition, sociodemographic characteristics and traditional cardiovascular risk factors may also contribute to disparities in outcomes compared with those of the general population. The aim of this study was to investigate the timing, patterns, and combinations of CVDs, as well as associated morbidity, mortality, and sociodemographic factors, in CAYAs with CVD compared with matched controls with CVD. METHODS: A register-based cohort study consisting of all Swedish cancer patients under 25 years old and during a 63-year observation time was used. CAYAs and controls with CVD (n = 58,981) were included and compared in terms of the timing and combinations of CVD, and mortality. RESULTS: The median age at first CVD was 41.8 years in CAYAs and 49.6 years in controls (p < 0.0001), with male CAYAs being the youngest at 25.0 years. During a median follow-up of 34.6 years, most CAYAs (65.2%) developed one CVD, while two or three coexisting CVDs occurred in 20.2% and 8.2%, respectively. Mostly hypertension in combination with cerebrovascular disease, ischemic heart disease and arrhythmias. More than three CVDs were more common in CAYAs than in controls (6.4% vs. 5.9%). A total of 21.8% of the CAYAs died, and the risk of all-cause mortality after the first CVD was 2.43-fold greater (hazard ratio (HR) 95% confidence interval (CI) 2.31-2.54, p < 0.0001), and for cardiovascular mortality, the risk was 2.17-fold greater (HR 95% CI 2.02-2.33, p < 0.0001) than that of the controls. In CAYAs with CVD, older age, male sex, and living in the central part of Sweden were associated with higher mortality, whereas higher education and marriage were protective (p < 0.0001). CONCLUSIONS: Compared with controls CAYAs develop advanced CVD and combinations of multiple CVDs earlier in life, and they have a greater risk of all-cause and cardiovascular mortality. Factors associated with increased mortality risk include male sex and geographic variation, whereas marriage and higher education appear to be protective.
3. Real-world anticoagulant use and clinical outcomes in postoperative atrial fibrillation after coronary artery bypass grafting: a nationwide practice-based cohort from the Netherlands Heart Registration.
In 10,750 linked POAF patients after isolated CABG, 43.6% received OAC (increasing over time). Although crude thromboembolic mortality was lower with OAC, survival differences disappeared when analyses started 30 days postoperatively, and most patients discontinued OAC by 1 year. Findings support exploring time-limited anticoagulation.
Impact: Addresses a common, practice-variable scenario with large-scale real-world data, suggesting that prolonged OAC may not improve long-term survival after POAF following CABG.
Clinical Implications: Consider time-limited anticoagulation and early de-escalation in CABG-related POAF, balancing thromboembolic and bleeding risks, and prioritize individualized reassessment beyond 30 days.
Key Findings
- Among POAF patients, 43.6% started OAC, increasing from 38.7% (2013) to 53.7% (2022).
- Crude thromboembolic mortality was lower with OAC (0.04 vs 0.42 per 100 patient-years) and bleeding-related mortality remained low.
- From 30 days postoperatively onward, survival analyses showed no significant differences between OAC and antiplatelet groups; most patients discontinued OAC by 1 year, with only 10.3% continuing for 10 years.
Methodological Strengths
- Nationwide registry linked to mortality and pharmacy data over a decade, with clear exclusion of prior AF/preoperative OAC.
- Large sample enabling cause-specific mortality analyses and temporal trends in OAC use.
Limitations
- Retrospective design with confounding by indication and potential misclassification of POAF duration/severity and OAC exposure.
- Lack of randomized assignment and limited granular bleeding/thromboembolism adjudication beyond mortality.
Future Directions: Prospective trials of time-limited anticoagulation in POAF after CABG, with stratification by stroke and bleeding risk and dynamic rhythm monitoring.
BACKGROUND: Postoperative atrial fibrillation (POAF) occurs in 15-40% of patients following coronary artery bypass grafting (CABG). Existing risk scores are unsuited to its transient nature, and evidence for long-term oral anticoagulation (OAC) remains limited. Although guidelines suggest balancing thromboembolic and bleeding risk, unclear recommendations and limited real-world data drive practice variation. This study evaluated OAC use and outcomes in a national POAF cohort after CABG. METHODS: This retrospective study included adults undergoing isolated CABG (2013-2022) from the Netherlands Heart Registration, linked to mortality and pharmacological data from Statistics Netherlands. Patients with prior atrial fibrillation or preoperative OAC were excluded. Outcomes included short-term complications and long-term cause-specific mortality, comparing OAC with antiplatelets. RESULTS: Among 44,601 CABG patients, 11,054 (24.8%) developed POAF. Of these, 10,750 were successfully linked. Mean age was 68.9 years; 81.7% were male. OAC therapy was initiated in 43.6% of patients, rising from 38.7% (2013) to 53.7% (2022). Within 30 days, mortality was 1.6%, cerebrovascular events 1.3%, and bleeding reintervention 5.4%. Most discontinued OAC after one year, while 10.3% continued for 10 years. Crude thromboembolic mortality was lower among OAC users (0.04 vs. 0.42 per 100 patient-years), while bleeding-related mortality remained low (0.00 vs. 0.08). However, survival analyses from 30 days postoperatively showed no significant differences between groups. CONCLUSIONS: Among POAF patients after CABG, crude mortality was lower in OAC users, but no survival benefit was observed from 30 days onward. Low long-term OAC continuation without excess thromboembolic mortality suggests the potential value of time-limited anticoagulation strategies.